Curology Exit Readiness Telehealth: What It Costs to Wait

Curology was the standout story of the COVID telehealth boom: a $1.15 billion valuation, a subscription model built on personalized prescription skincare, and a founder-CEO with a real growth story. Five years later, the company is on its third CEO, has rebuilt its supply chain twice, and now sells alongside CPG brands on the shelves of Target, CVS, Walmart, and Amazon. It never went public. It never sold. And the exit window that closed on the rest of the telehealth cohort in 2021 is one Curology is still trying to reopen.

For founders and operators watching the beauty and personal care category, Curology's path from unicorn to hybrid Rx-and-retail operator is a case study in what happens when a company misses its moment, and what it actually takes to earn a second one.

Why did missing the 2021 exit window cost Curology so much?

Curology hit unicorn status during the same window that took its closest competitors public. Hims & Hers went public via a $1.6 billion SPAC merger in January 2021, while Curology stayed private through Series D. That single decision, or the absence of one, put Curology on a different trajectory than the peers it was most often compared to.

Hims & Hers now carries a public market cap of roughly $7.9 billion as of August 2026, more than six times the value at which it went public. Ro, still private, raised at a $5 billion valuation in March 2021 and again at $7 billion in February 2022. Curology's last disclosed valuation, by contrast, remains anchored to its COVID-era Series D at roughly $1.15 billion, with revenue estimated at $200 to $250 million today, well off its 2021 peak of $200 million-plus in a market that has since scaled around it.

The cost wasn't just a lower number. It was optionality. Hims and Ro used their 2021 windows to raise permanent capital, diversify into GLP-1s and men's health, and build the balance sheets to weather telehealth's post-pandemic normalization. Curology stayed private and absorbed that normalization directly on its own P&L, which is exactly what forced the rebuild that followed.

Why was personalization both Curology's moat and its margin trap?

Curology's entire value proposition was a formula mixed for one face: a licensed provider assessed your skin, wrote a custom prescription, and a compounding pharmacy filled it just for you. That's a genuine moat: it's hard to compete with a product literally built around one customer's chemistry, and it's why Curology could charge subscription prices for what was, functionally, a medical service.

It's also expensive to run at scale. Custom compounding doesn't get cheaper the way mass manufacturing does; every formula still requires a provider consult, a pharmacist, and a batch of one. During the COVID surge, high customer volume and high willingness to pay covered those costs. As telehealth demand normalized industry-wide (visit volumes across the sector fell sharply from their pandemic peak), Curology was left with a cost structure built for a boom and a revenue base built for a plateau. The same personalization that won customers in 2020 was compressing margins by 2023.

How is Curology rebuilding its operations for exit readiness?

Curology's answer wasn't to abandon personalization. It was to stop asking personalization to carry the whole business. The rebuild ran on three tracks at once.

Right-sizing the provider network. As prescription volume normalized off its pandemic high, Curology shifted much of its clinical staffing from full-time to part-time and contract roles, matching provider capacity to actual demand instead of carrying peak-era headcount through a flatter period.

Consolidating compounding. Custom formulation moved from a more distributed model into a single, scaled compounding facility, trading some flexibility for the batch efficiency and quality consistency a buyer would expect to see in due diligence.

Building a real OTC business. This is the part that changed Curology's identity. Starting with Target online in December 2022 and Target stores in January 2023, Curology stood up a genuine over-the-counter product line and a separate DTC storefront (Curology Shop, July 2023), then expanded to Amazon in January 2024 and both CVS (roughly 3,800 stores) and Walmart (roughly 3,300 stores) in August 2024. That meant building an entirely separate supply chain for mass retail production, one that has to hit CPG-level margins and CPG-level operational discipline, not the boutique economics of a compounding pharmacy.

The retail bet is working operationally, at least by Curology's own account: the company has said Walmart shoppers convert to its prescription skincare line at five times the rate of its online-only customers, turning mass retail into a acquisition channel for the higher-margin Rx business rather than a cannibalization risk.

Three CEOs have overseen pieces of this transition. Founder Dr. David Lortscher moved from CEO to Chairman in 2022 as Heather Wallace, formerly of Revlon, took over to run the retail buildout. Wallace departed for a role at Galderma in 2025, and Kathy Savitt stepped in as CEO with a broader leadership reset. Leadership churn at this pace is often read as instability, but paired with a consistent operational thesis across all three regimes, it reads more like a board actively managing toward a specific outcome.

What does "earning the exit" look like from here?

A hybrid Rx-plus-retail business with CPG-level margins on the OTC side and a defensible clinical moat on the Rx side is, by design, attractive to more than one kind of buyer. Curology's rebuild has been shaped around three plausible paths.

A strategic acquirer in beauty or pharma, a L'Oréal or a Johnson & Johnson, gets a prescription dermatology brand with real retail distribution already built, sparing them the multi-year slog of getting a clinical skincare line onto CVS and Walmart shelves themselves. This is the highest-multiple outcome, but it requires Curology to prove the OTC margins and Rx retention are durable, not just improving.

A private equity roll-up values the same assets differently: predictable cash flow, a rationalized cost base, and a platform to bolt on adjacent telehealth or personalized-beauty brands. This path rewards exactly the operational discipline (right-sized provider network, consolidated compounding, CPG-grade supply chain) that Curology has spent the last three years building.

An IPO is the least likely near-term path. Public telehealth comps have taught the market to be skeptical of subscription-Rx stories without diversified revenue, which is precisely the gap Curology's retail pivot is meant to close. If it gets there, it will look far more like Hims & Hers today (a diversified consumer health platform) than the single-category telehealth story Curology was in 2021.

Whichever path materializes, the lesson for founders isn't "sell in the boom." It's that a missed window doesn't close the door. It changes the price of the door and the amount of proof a buyer will demand before opening it.

FAQ

Is Curology being acquired or preparing for an exit? Curology hasn't announced a sale, but its operational moves, provider network right-sizing, compounding consolidation, and a build-out of CPG-grade retail margins across Target, CVS, Walmart, and Amazon, align with the kind of readiness a strategic buyer or PE firm would require before a deal.

Why didn't Curology go public like Hims & Hers or Ro? Curology stayed private through its Series D and the 2021 window when Hims & Hers completed a SPAC merger and Ro raised at multibillion-dollar valuations. That decision left Curology to absorb telehealth's post-pandemic demand normalization on its own balance sheet rather than with newly raised public or late-stage capital.

What is Curology's current business model? Curology now runs a hybrid model: a prescription, compounded skincare subscription business alongside an over-the-counter retail line sold in Target, CVS, and Walmart stores and on Amazon, with the retail channel functioning as an acquisition funnel for the higher-margin Rx product.

Izba works with scaling beauty and personal care brands on exit readiness: the operational, financial, and supply chain work that turns a good story into a fundable one. If your team is asking what "exit-ready" actually looks like from the inside, let's talk.